Source-grounded facts extracted from CRYO CELL INTERNATIONAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CRYO CELL INTERNATIONAL INC received a nyse_american extension granted notice regarding other.
“May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N”
CRYO CELL INTERNATIONAL INC received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)).
“March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American procedures, the Company intends to submit a plan of”
CRYO CELL INTERNATIONAL INC amended credit facility of $8,000,000 with Susser Bank at Base Rate plus 4.25% for Term Loans, Base Rate plus 3.75% for Revolving Credit L maturing October 18, 2027 for RCF Note; July 29, 2032 for Term Note.
“Date to October 18, 2027 and extended the Maturity Date of the Term Note to July 29, 2032. Revolving Credit Limit. The Amendment revised the revolving credit commitment to $8,000,000. Applicable Margin . The Amendment revised the Applicable Margin per annum as set forth below: Base Rate with respect to Term Loans Base Rate with respect to Revolving Credit”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.